Advent Life Sciences — Full Portfolio

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)RSRobert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)SOSteven O'Day(Chief Medical Officer)in

Co-investorsGRGrazia Equity GmbHHEHEALTHCARE ROYALTY PARTNERSOBOberland CapitalCOCommodore CapitalINInvusLILigand Pharmaceuticals+1 more

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)EDElisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsCHChiesi VenturesCOColumbus Venture PartnersDRDroia VenturesFOForesite CapitalJAJazzya InvestmentsMEMedicxi+6 more

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

FEFuad El-Hibri(Director, Executive Officer)inRGRobert G Kramer(Executive Officer)inKatherine Strei(Executive Officer)ARAdam R Havey(Executive Officer)inDJDaniel J Abdun-Nabi(Executive Officer, Director)inJCJoseph C. Papa(President, CEO and Director)

Co-investorsOROrbiMed

Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19.

BiotechHealthtech

Co-investorsSOSolas BioVentures

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

DCDaniel Chung(Chief Medical Officer)inLBLance Baldo(Chief Executive Officer)inASAbraham Scaria(Chief Scientific Officer)in

Co-investorsFOForbionOXOxford Science EnterprisesTCTCG Crossover

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)in

Co-investorsGIGilde HealthcareINIndex VenturesMEMedicxiPFPfizer VenturesPFPfizer Venture InvestmentsRERedwood Ventures

Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent.

BiotechHealthtechImpact & Social GoodMedical DevicesParis, FR

Massimo BorieroinDPDmitry ParamonovinJohn FatuhiSandra BensoussaninABAngelita BriffainOmar Camille Kamlin

Co-investorsBPBpifrance

Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring.

BiotechHealthtechMedical DevicesCosta Mesa, US

Co-investorsBRBroadview VenturesGOGood Growth CapitalVEVensana Capital

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.

BiotechDeep TechHealthtechParis, FR

Co-investorsBIBioqube VenturesBPBpifrancePUPureos BioventuresADAdBio partners

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

MGMichael Gilman(Executive Officer, Director)inMDMark DeLong(CEO)inDNDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardCCColleen Cuffaro(Director)inAEAlan E. Walts(Director)in

Board seatRPRaj ParekhAWAlan Walts· per SEC Form D

Co-investorsCACanaan PartnersPFPfizer VenturesHBHBM Healthcare InvestmentsHBHBM PartnersNENextech InvestOUOUP (Osage University Partners)+2 more

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.

BiotechHealthtechCambridge, US

DTDamia Tormo(President, CEO, Treasurer and Founder)inJSJoe Suarez(Executive Officer)MNMaria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in

BoardAndre Hoekema(Director)

Board seatRPRaj ParekhAWAlan Walts· per SEC Form D

Co-investorsSOSound BioventuresCOColumbus Venture Partners

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Board seatKBKatrine Bosley· per SEC Form D · $15M raise · filed Feb 2019

Co-investorsCYCycad Group LLCLULux CapitalMCMC Healthcare VenturesALAlexandriaAUAuriga PartnersBIBill & Melinda Gates Foundation+1 more

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)HSHenry Skinner(Director)inVikas Goyal(Director)

Board seatRPRaj Parekh· per SEC Form D

Co-investorsGUGurnet Point CapitalNONovartis Venture FundRORoche Venture Fund

HealthtechFremont, US

Anton Clifford(Executive Officer)inJLJames Leech(Executive Officer)inCGChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)

Board seatSMShahzad Malik· per SEC Form D

Co-investorsLILightstone VenturesNENew Enterprise Associates (NEA)RURunway Growth CapitalGBGBS Venture Partners Ltd.GIGilde HealthcareMOMorgenthaler+1 more

HealthtechCarlsbad, US

CSChristoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVBVince Burgess(Director)inJohn Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Co-investorsOROrbiMedXEXeraya CapitalDEDeerfield Management CompanyFOFormation GroupGEGE VenturesINIndex Ventures

Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.

Co-investorsBIBirk VentureHEHealthCapABAbingworth

AlphaRose develops genetic technologies and treatments for children with rare genetic diseases, aiming to make and commercialize such medicines at scale.

BiotechHealthtech

Co-investorsSUSuncoast Ventures

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

LMLouise Modis(Chief Executive Officer)inMPMartin Pass(Chief Development Officer)inGBGiles Brown(Executive VP Drug Discovery)in

Co-investorsNONovartis Venture FundSVSV Health InvestorsDEDementia Discovery FundEUEuropean Investment FundFOForbionGIGilde Healthcare+2 more

BiotechHouston, US

AGAmato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)inGail McIntyre(Chief Executive Officer)LSLeonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)

Co-investors3E3E Bioventures CapitalESEshelman Ventures, LLC

Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias.

HardwareHealthtechMedical Devices

Co-investorsHIHigh Tech GruenderfondsEAEarlybird Venture CapitalGIGilde HealthcareHTHTGF

AviadoBio is a biotech company focused on frontotemporal dementia (FTD), a form of early-onset dementia.

BiotechHealthtechMedical Devices

David Cooper(Chief Medical Officer)Farah Speer(SVP, Communications and External Relations)

Aura provides AI-powered digital security and protection services for families and individuals across all ages.

AI & Machine LearningConsumerCybersecurityDigital HealthWellness & FitnessBoston, US

HRHari Ravichandran(Founder)inBDBrian DeCenzo(President & Chief Financial Officer)inTCThomas Clayton(President & Chief Operating Officer)AMAdam Medros(Chief Product Officer)inSarah Cherng(Chief AI Officer)KLKristin Lewis(Chief Product Officer (prior to May 2026 CPO reorganization; promoted from SVP Product, May 2022))in

Co-investorsACAccelGEGeneral CatalystGRGranite HillMAMachina VenturesPAPartech VenturesSISignalFire+7 more

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

CSChris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDYDo Young Lee(Co-Founder)YBYoun Bok Lee(Co-Founder)inLDLisa Deschamps(Chief Executive Officer)inGFGraeme Fielder(Chief Operating Officer)inABAlex Bloom(Chief Development Officer)in

Co-investorsDEDementia DiscoveryF-F-Prime CapitalLILifeArc VenturesMOMonograph Capital PartnersNENew Enterprise Associates (NEA)SVSV Health Investors

Axonics Modulation, now part of Boston Scientific, develops medical devices in the field of neuromodulation therapies for patients.

HealthtechMedical Devices

RCRaymond Cohenin

Co-investorsAPAPERTURE Venture PartnersLOLongitude CapitalGIGilde HealthcareNENeomed Management

Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.

HealthtechMedical DevicesIrvine, US

Michael Williamson(Executive Officer)Dan L. Dearen(Executive Officer)inRCRaymond Cohen(Executive Officer, Director)in

BoardDarren Cai(Director)Raphael Wisniewski(Director)Erik Amble(Director)

Co-investorsANAndera PartnersLOLongitude CapitalGIGilde Healthcare

Aditya Mhatre(Founder)Divya Gupta(Founder)Nilam Ganenthiran(Founder)Stuart Szabo(Founder)

Co-investorsALAlphaDriveGEGeneral CatalystHAHARPER COURT VENTURESHUHuman CapitalILIllinois VenturesMAManta Ray Ventures

Biocartis develops molecular diagnostic testing systems for cancer, with a focus on enabling personalized medicine through rapid, in-house biomarker analysis.

BiotechDigital HealthHealthtechMedical DevicesMechelen, BE

Co-investorsKOKorysNENew Rhein Healthcare Investors, LLCPMPMV

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsECEcoR1 CapitalFOForesite CapitalGEGeneral AtlanticLILifeSci Venture PartnersMEMedicxiOBOberland Capital+4 more

Cyted Health develops diagnostics for earlier and more accurate detection of esophageal disease, including its EndoSign capsule sponge cell collection device and molecular diagnostics, intended for clinicians screening for conditions such as Barrett's Esophagus and esophageal cancer.

BiotechHealthtechMedical Devices

Co-investorsEQEQT Life Sciences

Emergent is a platform that enables operations teams to build internal tools, dashboards, and AI agents on top of existing systems using natural language prompts, without requiring developer involvement.

AI & Machine LearningConsumerDeveloper ToolsEnterprise SoftwareFuture of WorkSaaSSan Francisco, US

MJMukund Jha(CEO)inMJMadhav Jha(CTO)inRBRituparna Bose(Founder)inRMRohit Mittal(Founder)inMukund Jha Madhav Jha(Founder)Nilotpal Goswami(Human Resources)

Co-investorsKHKhosla VenturesLILightspeed India PartnersSOSoftBank Vision FundTOTogether FundTRTranspose Platform ManagementY Y Combinator+4 more

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

CPClaude PerreaultPTPierre Thibault

Co-investorsCACambridge Innovation CapitalCTCTI Life Sciences Fund L.P.ADadMare BioInnovationsFOFonds de solidarité FTQ

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsAIAisling CapitalAMAMR Action FundASAstellas Venture Management LLCBRBrace PharmaSOSofinnova PartnersSUSunstone Capital+4 more

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)inSASteven Axon(Chief Executive Officer)inHAHicham Alaoui(Chief Scientific Officer)inRMRose Marino(Chief Medical Officer)inPMPeter McWilliams(Chief Business Officer)GHGeoffrey Hird(Chief Technology Officer)in

Co-investorsASAsahi Kasei Corporate Venture CapitalCHChiesi VenturesCTCTI Life Sciences Fund L.P.MIMission Bay CapitalMIMission BiocapitalRERemiges Ventures, Inc.+6 more

Highlight builds AI software that reduces team coordination overhead by focusing on communication and collaboration between team members rather than individual productivity.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSSan Francisco, US

JLJoshua Lipson(Founder)inSSSergei Sorokin(Founder)inPim De WitteHaris Butt(Founder)JKJay Khatri(Founder)inJosh Lipson(Founder)

Co-investorsGEGeneral Catalyst35359 CapitalABAbstract VenturesCOCollaborative FundKHKhosla VenturesOMOMERS Ventures+9 more

Infinity provides cross-border payment infrastructure for businesses, enabling them to receive international payments with transparent pricing and RBI-compliant operations.

FintechBengaluru, IN

SCSourav Choraria(CEO)inSCSidharth Choraria(CTO)in

Co-investorsSCScript CapitalTOTouring CapitalY Y CombinatorLILiquid VenturesNONova Threshold Trust LimitedPEPeterson Venture Partners

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

MWMichael W. Dunne(Executive Officer, Promoter)inCNCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsBABay City CapitalCACanaan PartnersSOSofinnova VenturesDODolby Family VenturesFRFrazier Life SciencesSOSofinnova Venture Partners

Little Dog Communications is a biotech communications firm that helps life science companies translate complex scientific and technical concepts into clear narratives for investors, media, and other stakeholders.

BiotechMarketing TechSan Diego, US

Jessica Yingling(Ph.D., President)

Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.

HardwareHealthtechMedical DevicesCarlsbad, US

EFEarl Fender(President & CEO)inLHLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBSBick Sellers(Executive Officer)inTAThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)

Co-investorsAPAPERTURE Venture PartnersB B Capital GroupB4B4 CapitalDEDecheng CapitalENEndeavour VisionLOLongitude Capital+3 more

Co-investorsFOFountain Healthcare PartnersOROrbiMedCOColumbus Venture PartnersFOForbionRERedwood Ventures

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.

BiotechMedical DevicesEdinburgh, GB

NCNeil Carragher(Founder)in

Co-investorsLILifeArc VenturesOLOld College Capital

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)DADr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)SASun Altbach(Executive Officer, Director)in

Co-investorsLULumira VenturesOROrbiMed

Proximie provides a cloud-based operating system for connected operating rooms, giving medtech companies and hospitals real-time OR connectivity, structured surgical data, and AI-driven insights.

AI & Machine LearningDigital HealthMedical DevicesSaaSAltrincham

NHNadine Hachach-Haram(Founder)inJLJonathan Lim(Director)inSHScott Huennekens(Director)in

BoardMohammed Shahzad Ahmed Malik(Director)

Co-investorsCACapria VenturesCECedar Mundi VenturesCOCOTU VenturesDRDraper AssociatesF-F-Prime CapitalQUQuesta Capital+6 more

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

MSMoin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSOSofinnova PartnersFOForbionGIGilde HealthcareBRBritish Patient Capital

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsNONovartis Venture FundNONovo Holdings

Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.

Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)LULuma GroupSASanofi VenturesABAbingworth+11 more

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

MKMatthew Kapustain

Co-investorsALALS Investment FundFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSRIRidgeback CapitalFOForbion

Co-investorsAIAisling CapitalSOSofinnova Ventures

Zyme Communications provides PR and marketing services to life science companies across Europe and the USA, helping them build visibility with investors, commercial partners, and customers through specialized communications and media outreach.

BiotechMarketing TechSaaS